Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 240

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes

Open access
Schweizer, A., Couturier, A., Foley, J. E., Dejager, S. · 2007 · Diabetic Medicine

Abstract

Aims To evaluate the ability of vildagliptin and metformin to sustain reductions in HbA 1c over a 1‐year treatment period in drug‐naïve patients with Type 2 diabetes (Type 2 DM). Methods Double‐blind, randomized, multicentre, active‐controlled, parallel‐group study of 52‐week treatment with vildagliptin (100 mg daily, n = 526) or metformin (titrated to 2000 mg daily, n = 254) in drug‐naïve patients (baseline HbA 1c = 7.5–11.0%). HbA 1c was measured periodically over 1 year. Results Vildagliptin and metformin each rapidly decreased HbA 1c from an equal baseline of 8.7%. Most of the HbA 1c reduction was attained by week 12, and the efficacy was sustained throughout 1‐year treatment with both agents. At the study end, significant HbA 1c reductions from baseline were seen with both vildagliptin (–1.0 ± 0.1%, P < 0.001) and metformin (–1.4 ± 0.1%, P < 0.001); however, statistical non‐inferiority of 50 mg vildagliptin twice daily to 1000 mg metformin twice daily was not established. Body weight did not change during the 1‐year treatment with vildagliptin (0.3 ± 0.2 kg, P = 0.17) and decreased in metformin‐treated patients (–1.9 ± 0.3 kg, P < 0.001). The proportion of patients experiencing an adverse event was 70.1 vs. 75.4% in patients receiving vildagliptin and metformin, respectively. The proportion of patients experiencing a gastrointestinal adverse event was twofold higher in the metformin group, driven by a 3–4‐fold greater incidence of diarrhoea, nausea and abdominal pain. The incidence of hypoglycaemia was similarly low in both groups (< 1%). Conclusions A clinically meaningful decrease in HbA 1c that was sustained throughout a 1‐year treatment in drug‐naïve patients with Type 2 DM was seen with both metformin and vildagliptin monotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2007.02191.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 240

Metadata

Authors
Schweizer, A., Couturier, A., Foley, J. E., & Dejager, S.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2007-05-17
Volume
24
Issue
9
Pages
955-961
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2020638064
Cited by
240
References
7
FWCI
29.46
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1464-5491.2007.02191.x
The paper
Schweizer, A., Couturier, A., Foley, J. E., & Dejager, S. (2007). Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2007.02191.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.